Cyprus in danger of medicinal products being withdrawn

17 March 2015

The Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) is concerned about the Minister of Health’s decision to proceed with a further 8.5% horizontal price cut on private sector medicines. This latest, one-sided measure may create problems in regards to the uninterrupted availability of medicines in the Cypriot market, says the trade group.

KEFEA has also expressed these concerns in writing to the Minister of Health with a letter that specified, among others: “Regarding your expressed intention to proceed with an added general price reduction in the range of 8.5%, we feel it is our duty to inform you that such a decision may potentially create problems in the uninterrupted availability of medicines in the Cypriot market. As also stressed in the study by the World Health Organization, it is important to ensure this will not have a spill-over effect in other countries that reference the Cypriot prices, which could jeopardise availability of these products in Cyprus.”

Added to recent 5% cut, overall total comes to 20%

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK